Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) PT at $51.22

Twist Bioscience Co. (NASDAQ:TWST) has received an average rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $51.22.

A number of equities research analysts have issued reports on the company. The Goldman Sachs Group increased their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Leerink Partners boosted their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Barclays reduced their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. Finally, Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 2,261 shares of the business’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $43.09, for a total value of $97,426.49. Following the completion of the sale, the chief operating officer now owns 159,483 shares in the company, valued at approximately $6,872,122.47. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, COO Patrick John Finn sold 2,261 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49. Following the transaction, the chief operating officer now owns 159,483 shares of the company’s stock, valued at $6,872,122.47. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total value of $35,789.36. Following the completion of the transaction, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,300 shares of company stock worth $1,801,822 in the last quarter. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. EdgeRock Capital LLC purchased a new position in Twist Bioscience during the 2nd quarter valued at about $43,000. Blue Trust Inc. raised its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter valued at about $61,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares in the last quarter.

Twist Bioscience Trading Up 0.9 %

Shares of TWST opened at $40.60 on Friday. The company’s 50-day moving average price is $43.83 and its 200 day moving average price is $44.80. Twist Bioscience has a 12-month low of $14.42 and a 12-month high of $60.90. The firm has a market cap of $2.36 billion, a P/E ratio of -12.08 and a beta of 1.77.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s revenue for the quarter was up 27.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.01) earnings per share. Equities research analysts forecast that Twist Bioscience will post -3.13 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.